dc.contributor.author | Eskazan, AHMET EMRE | |
dc.contributor.author | Keskin, Dilek | |
dc.date.accessioned | 2021-03-05T19:19:13Z | |
dc.date.available | 2021-03-05T19:19:13Z | |
dc.identifier.citation | Eskazan A. E. , Keskin D., "Radotinib and its clinical potential in chronic-phase chronic myeloid leukemia patients: an update.", Therapeutic advances in hematology, cilt.8, ss.237-243, 2017 | |
dc.identifier.issn | 2040-6207 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_ceafb581-9c73-4821-9ed5-c786fd25deba | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/136719 | |
dc.identifier.uri | https://doi.org/10.1177/2040620717719851 | |
dc.language.iso | eng | |
dc.title | Radotinib and its clinical potential in chronic-phase chronic myeloid leukemia patients: an update. | |
dc.type | Makale | |
dc.relation.journal | Therapeutic advances in hematology | |
dc.contributor.department | İstanbul Üniversitesi , , | |
dc.identifier.volume | 8 | |
dc.identifier.startpage | 237 | |
dc.identifier.endpage | 243 | |
dc.contributor.firstauthorID | 180382 | |